Capricor Therapeutics, Inc. — Income Charts
4 quarters of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$11M
R&D
$15M
D&A
$376K
Operating Income
$-13M
EBITDA
$376K
Interest Expense
—
Interest Income
—
Net Income
$-13M
Operating Margin
-575.2%
Net Margin
-555.2%
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost
$210K
Revenue YoY Variation
-7.9%
Income YoY Variation
-89.5%
Revenue QoQ Variation
392.1%
Income QoQ Variation
-12.2%